Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 4.26
TRXC's Cash-to-Debt is ranked higher than
53% of the 205 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. TRXC: 4.26 )
Ranked among companies with meaningful Cash-to-Debt only.
TRXC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: No Debt Max: No Debt
Current: 4.26
0.05
No Debt
Equity-to-Asset 0.72
TRXC's Equity-to-Asset is ranked lower than
58% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. TRXC: 0.72 )
Ranked among companies with meaningful Equity-to-Asset only.
TRXC' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.91  Med: 0.82 Max: 0.95
Current: 0.72
-3.91
0.95
Debt-to-Equity 0.12
TRXC's Debt-to-Equity is ranked higher than
75% of the 142 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.37 vs. TRXC: 0.12 )
Ranked among companies with meaningful Debt-to-Equity only.
TRXC' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.37  Med: 0.08 Max: 0.91
Current: 0.12
-2.37
0.91
Debt-to-EBITDA -1.37
TRXC's Debt-to-EBITDA is ranked lower than
99.99% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.88 vs. TRXC: -1.37 )
Ranked among companies with meaningful Debt-to-EBITDA only.
TRXC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.37  Med: -0.28 Max: -0.01
Current: -1.37
-1.37
-0.01
Piotroski F-Score: 4
Altman Z-Score: 1.75
Beneish M-Score: 3.67
WACC vs ROIC
22.95%
-57.84%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -292.28
TRXC's Operating Margin % is ranked lower than
97% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.41 vs. TRXC: -292.28 )
Ranked among companies with meaningful Operating Margin % only.
TRXC' s Operating Margin % Range Over the Past 10 Years
Min: -9129.43  Med: -1554.37 Max: -292.28
Current: -292.28
-9129.43
-292.28
Net Margin % -658.25
TRXC's Net Margin % is ranked lower than
97% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.18 vs. TRXC: -658.25 )
Ranked among companies with meaningful Net Margin % only.
TRXC' s Net Margin % Range Over the Past 10 Years
Min: -9389.53  Med: -2036.23 Max: -658.25
Current: -658.25
-9389.53
-658.25
ROE % -82.54
TRXC's ROE % is ranked lower than
86% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.43 vs. TRXC: -82.54 )
Ranked among companies with meaningful ROE % only.
TRXC' s ROE % Range Over the Past 10 Years
Min: -808.14  Med: -155.77 Max: -31.4
Current: -82.54
-808.14
-31.4
ROA % -57.15
TRXC's ROA % is ranked lower than
87% of the 206 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. TRXC: -57.15 )
Ranked among companies with meaningful ROA % only.
TRXC' s ROA % Range Over the Past 10 Years
Min: -245.7  Med: -108.52 Max: -24.47
Current: -57.15
-245.7
-24.47
ROC (Joel Greenblatt) % -228.51
TRXC's ROC (Joel Greenblatt) % is ranked lower than
92% of the 204 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.63 vs. TRXC: -228.51 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TRXC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2835.71  Med: -1272.65 Max: -228.51
Current: -228.51
-2835.71
-228.51
3-Year Revenue Growth Rate 90.00
TRXC's 3-Year Revenue Growth Rate is ranked lower than
96% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. TRXC: 90.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TRXC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -79.1 Max: 90
Current: 90
0
90
3-Year EBITDA Growth Rate 18.20
TRXC's 3-Year EBITDA Growth Rate is ranked higher than
65% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.00 vs. TRXC: 18.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TRXC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -29.1 Max: 73.1
Current: 18.2
0
73.1
3-Year EPS without NRI Growth Rate -14.90
TRXC's 3-Year EPS without NRI Growth Rate is ranked higher than
68% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.90 vs. TRXC: -14.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TRXC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -67.7 Max: 70.6
Current: -14.9
0
70.6
GuruFocus has detected 2 Warning Signs with TransEnterix Inc TRXC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TRXC's 30-Y Financials

Financials (Next Earnings Date: 2019-03-06 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

TRXC Guru Trades in

TRXC Guru Trades in

Q2 2018

TRXC Guru Trades in Q2 2018

Joel Greenblatt 22,998 sh (New)
» More
Q3 2018

TRXC Guru Trades in Q3 2018

Joel Greenblatt 31,132 sh (+35.37%)
» More
» Details

Insider Trades

Latest Guru Trades with TRXC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:BOM:531768, XKRX:119610, SZSE:300453, NAS:ELGX, MIL:SFL, NAS:ATRS, XKRX:049180, HKSE:00801, NAS:UTMD, SZSE:300030, ROCO:6491, SHSE:603880, XSWX:CLTN, NAS:PLSE, TSE:6823, SZSE:300573, ROCO:6499, NAS:SIEN, SZSE:300246, XSWX:VBSN » details
Traded in other countries:2TX.Germany,
Headquarter Location:USA
TransEnterix Inc is a medical device company engaged in the development and commercialization of a robotic assisted surgical system called the SurgiBot System. The SurgiBot System is a single-port, robotically enhanced laparoscopic surgical platform.

TransEnterix Inc is a medical device company developing the use of robotics for minimally invasive surgery. Its key business is the commercialization and development of the ALF-X Surgical Robotic System, a multiport robotic system that allows multiple robotic arms to control instruments and a camera. TransEnterix also sells the SurgiBot System, a single-port, robotically enhanced laparoscopic surgical platform. The ALF-X system gives surgeons haptic feedback and the ability to move its camera via eye movement. It also includes three-dimensional high-definition vision technology and motions similar to traditional laparoscopic surgeries. The instruments for this system are primarily reusable.

Ratios

vs
industry
vs
history
PB Ratio 3.91
TRXC's PB Ratio is ranked higher than
60% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.45 vs. TRXC: 3.91 )
Ranked among companies with meaningful PB Ratio only.
TRXC' s PB Ratio Range Over the Past 10 Years
Min: 0.5  Med: 3.2 Max: 42.58
Current: 3.91
0.5
42.58
PS Ratio 30.71
TRXC's PS Ratio is ranked lower than
97% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.48 vs. TRXC: 30.71 )
Ranked among companies with meaningful PS Ratio only.
TRXC' s PS Ratio Range Over the Past 10 Years
Min: 1.11  Med: 156.92 Max: 10750
Current: 30.71
1.11
10750
EV-to-EBIT -21.69
TRXC's EV-to-EBIT is ranked lower than
99.99% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.93 vs. TRXC: -21.69 )
Ranked among companies with meaningful EV-to-EBIT only.
TRXC' s EV-to-EBIT Range Over the Past 10 Years
Min: -47.1  Med: -4.3 Max: -0.1
Current: -21.69
-47.1
-0.1
EV-to-EBITDA -42.75
TRXC's EV-to-EBITDA is ranked lower than
99.99% of the 138 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.49 vs. TRXC: -42.75 )
Ranked among companies with meaningful EV-to-EBITDA only.
TRXC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -92.7  Med: -4.4 Max: -0.1
Current: -42.75
-92.7
-0.1
EV-to-Revenue 29.76
TRXC's EV-to-Revenue is ranked lower than
96% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.57 vs. TRXC: 29.76 )
Ranked among companies with meaningful EV-to-Revenue only.
TRXC' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.1  Med: 110.5 Max: 17252.9
Current: 29.76
0.1
17252.9
Current Ratio 8.84
TRXC's Current Ratio is ranked lower than
56% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.57 vs. TRXC: 8.84 )
Ranked among companies with meaningful Current Ratio only.
TRXC' s Current Ratio Range Over the Past 10 Years
Min: 0.15  Med: 5.37 Max: 43.89
Current: 8.84
0.15
43.89
Quick Ratio 7.99
TRXC's Quick Ratio is ranked lower than
51% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.87 vs. TRXC: 7.99 )
Ranked among companies with meaningful Quick Ratio only.
TRXC' s Quick Ratio Range Over the Past 10 Years
Min: 0.15  Med: 5.14 Max: 43.89
Current: 7.99
0.15
43.89
Days Inventory 286.13
TRXC's Days Inventory is ranked lower than
100% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.35 vs. TRXC: 286.13 )
Ranked among companies with meaningful Days Inventory only.
TRXC' s Days Inventory Range Over the Past 10 Years
Min: 57.06  Med: 116.83 Max: 2476.81
Current: 286.13
57.06
2476.81
Days Sales Outstanding 103.58
TRXC's Days Sales Outstanding is ranked higher than
93% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.97 vs. TRXC: 103.58 )
Ranked among companies with meaningful Days Sales Outstanding only.
TRXC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.95  Med: 92.5 Max: 149.22
Current: 103.58
47.95
149.22
Days Payable 72.42
TRXC's Days Payable is ranked higher than
95% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 54.66 vs. TRXC: 72.42 )
Ranked among companies with meaningful Days Payable only.
TRXC' s Days Payable Range Over the Past 10 Years
Min: 72.42  Med: 589.33 Max: 1360.3
Current: 72.42
72.42
1360.3

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -46.70
TRXC's 3-Year Average Share Buyback Ratio is ranked lower than
89% of the 143 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -5.00 vs. TRXC: -46.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TRXC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -124.3  Med: -16 Max: 0
Current: -46.7
-124.3
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 38.00
TRXC's Price-to-Net-Cash is ranked lower than
99.99% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.15 vs. TRXC: 38.00 )
Ranked among companies with meaningful Price-to-Net-Cash only.
TRXC' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.58  Med: 9.28 Max: 258.43
Current: 38
0.58
258.43
Price-to-Net-Current-Asset-Value 15.20
TRXC's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.83 vs. TRXC: 15.20 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
TRXC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.39  Med: 6.98 Max: 153.33
Current: 15.2
0.39
153.33
Price-to-Tangible-Book 12.67
TRXC's Price-to-Tangible-Book is ranked lower than
99.99% of the 167 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.77 vs. TRXC: 12.67 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TRXC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.26  Med: 6.32 Max: 311.67
Current: 12.67
0.26
311.67
Price-to-Median-PS-Value 0.20
TRXC's Price-to-Median-PS-Value is ranked higher than
97% of the 160 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.13 vs. TRXC: 0.20 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TRXC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 0.1 Max: 50
Current: 0.2
0.01
50
Earnings Yield (Greenblatt) % -4.60
TRXC's Earnings Yield (Greenblatt) % is ranked lower than
87% of the 207 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. TRXC: -4.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TRXC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -8571.4  Med: -23.5 Max: 24846.3
Current: -4.6
-8571.4
24846.3

More Statistics

Revenue (TTM) (Mil) $19.98
EPS (TTM) $ -0.73
Beta3.37
Volatility124.52%
52-Week Range $1.27 - 6.98
Shares Outstanding (Mil)216.12

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 24 40 72
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.34 -0.26 -0.19
EPS without NRI ($) -0.34 -0.26 -0.19
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}